secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001104659-26-016797
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea reports second partial response for APR-1051; endometrial cancer with PPP2R1A mutation
--------------------------------------------------------------------------------

- Second unconfirmed partial response (uPR) at 220 mg dose: 50% tumor shrinkage (RECIST v1.1) and CA-125 drop from 362 to 47 U/mL (-87%).
- Both uPRs observed in endometrial cancer patients with PPP2R1A mutations; both remain on therapy with only Grade 1 adverse events.
- Total 22 patients dosed (10–220 mg); five stable disease across four tumor types including HPV-positive HNSCC and FBXW7-mutated colon cancer.
- First uPR previously reported at 150 mg; data support genomically guided WEE1 inhibition with favorable tolerability to date.
- Next data update expected Q2 2026; enrollment continues at 220 mg and expansion in PPP2R1A endometrial and HPV-positive HNSCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926016797/0001104659-26-016797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926016797/tm266669d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-016797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer